Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.39 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.39 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.39 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.31 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9730154 | 0.77 | — | — | |
| SCHEMBL5462613 | 0.77 | — | — | |
| SCHEMBL12158332 | 0.77 | — | — | |
| SCHEMBL26940423 | 0.77 | — | — | |
| SCHEMBL846734 | 0.77 | — | — | |
| SCHEMBL12818554 | 0.77 | CYP3A4 (0.35) | — | |
| SCHEMBL31191911 | 0.74 | SLC1A3 (0.32) | SLC1A3SLC1A2SLC1A1 | |
| Ammonia Solution, Strong SCHEMBL27753053 | 0.74 | TP53 (0.38) | TP53SLC1A3SLC1A2SLC1A1SLC7A5 | |
| SCHEMBL2034471 | 0.74 | SMN1; SMN2 (0.44) | KMT2A | |
| SCHEMBL17010828 | 0.74 | SLC1A3 (0.54) | TP53SLC1A3SLC1A2SLC1A1SLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3860712-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | Vertex Pharmaceuticals Incorporated (US) | 2021-08-11 | — | — | EP | claimed |
| US-20210179587-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | VERTEX PHARMACEUTICALS INCORPORATED | 2021-06-17 | — | — | US | claimed |
| WO-2020081257-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-04-23 | — | — | WO | claimed |
| CN-107602565-B | Synthesis method of 2-amino-6-methyl- [1, 2, 4] -triazolo [1, 5-a ] pyrimidine-5-ketone | 浙江大学 | 2020-03-31 | — | — | CN | claimed |
| US-20030236397-A1 | Process for preparing beta-L-2'deoxy-thymidine | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-12-25 | — | — | US | claimed |
| WO-2003087118-A2 | METHOD FOR PRODUCING BETA-L-2'DEOXY-THYMIDINE | BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG (DE) | 2003-10-23 | — | — | WO | claimed |
| US-20250153438-A1 | METHOD FOR SEPARATING POLYMER ELEMENTS, WHICH WERE PRODUCED BY AN ADDITIVE MANUFACTURING METHOD, BY MEANS OF GRANULAR MEDIA | 84J GmbH & Co. KG (DE) | 2025-05-15 | — | — | US | disclosed |
| US-20240287063-A1 | METHIONINE ADENOSYLTRANSFERASE 2A INHIBITOR | NANJING CHIA TAI TIANQING PHARMACEUTICAL CO., LTD. (CN) | 2024-08-29 | — | — | US | disclosed |
| CN-117412967-A | Methionine adenosine transferase 2A inhibitors | 南京正大天晴制药有限公司 | 2024-01-16 | — | — | CN | disclosed |
| US-20230265080-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | VERTEX PHARMA (US) | 2023-08-24 | — | — | US | disclosed |
| US-11623924-B2 | Modulators of alpha-1 antitrypsin | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-04-11 | — | — | US | disclosed |
| EP-3860712-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | Vertex Pharmaceuticals Incorporated (US) | 2021-08-11 | — | — | EP | disclosed |
| EP-3650442-B1 | METHOD FOR THE PREPARATION OF DIFLUOROMETHYL PYRAZOLE CARBOXYLIC ALKYL ESTER AND ITS ACID | LONZA SOLUTIONS AG (CH) | 2021-06-30 | — | — | EP | disclosed |
| EP-2055694-A1 | Method for manufacturing alkyl-3-alkoxyprop-2-enoates | LONZA AG (CH) | 2009-05-06 | — | — | EP | disclosed |
| WO-2008073311-A2 | SUBSTITUTED DIAZEPINE SULFONAMIDES AS BOMBESIN RECEPTOR SUBTYPE-3 MODULATORS | MERCK & CO., INC. (US) | 2008-06-19 | — | — | WO | disclosed |
| US-20030236397-A1 | Process for preparing beta-L-2'deoxy-thymidine | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-12-25 | — | — | US | disclosed |
| WO-2003087118-A2 | METHOD FOR PRODUCING BETA-L-2'DEOXY-THYMIDINE | BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG (DE) | 2003-10-23 | — | — | WO | disclosed |
| US-6339090-B1 | FOR THERAPY OF BENIGN PROSTATIC HYPERPLASIA | MERCK & CO., INC. | 2002-01-15 | — | — | US | disclosed |
| WO-2000006565-A1 | ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2000-02-10 | — | — | WO | disclosed |
| EP-0302359-A2 | Positive photo-sensitive compositions | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-02-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287063-A1 | METHIONINE ADENOSYLTRANSFERASE 2A INHIBITOR | MAT2A, MAT2B, MAT1A | TP53 3417/4885SLC1A3 441/4885SLC1A2 164/4885 |
| US-20030236397-A1 | Process for preparing beta-L-2'deoxy-thymidine | TYMP, TYMS, DERA | TP53 2958/4885SLC1A3 2269/4885SLC1A2 1583/4885 |
| US-11623924-B2 | Modulators of alpha-1 antitrypsin | SERPINA2, SERPINA3, SERPINB1 | TP53 4492/4885SLC1A3 4281/4885SLC1A2 4521/4885 |
| US-20210179587-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | SERPINA2, SERPINA3, SERPINB1 | TP53 4492/4885SLC1A3 4281/4885SLC1A2 4521/4885 |
| US-20230265080-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | SERPINA2, SERPINA3, SERPINB1 | TP53 4492/4885SLC1A3 4281/4885SLC1A2 4521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.